Nigel Wray-backed Belluscura to raise £15 million for oxygen concentrator rollout


medical devices business backed by former Saracens rugby club chairman Nigel Wray is set to raise £15 million after revealing plans for a stock market listing.

Belluscura will use the funds for the roll out of its lightweight and portable oxygen concentrators that can replace cumbersome metal cylinders in treating lung diseases.

Its X-PLO2R device, which received approval from US regulators in March, is able to deliver up to 95% pure oxygen to patients 24 hours a day to help improve quality of life.

The London and Texas-based company will also look to progress other patents relating to oxygen enrichment devices and treatments.

Belluscura is expected to be valued at between £50 million and £55 million on AIM following the placing of shares with institutions later this month. Wray holds a 17% stake.

SPARK Advisory Partners is acting as adviser, while Dowgate Capital is sole broker and bookrunner on the placing.


READ  Watch Elizabeth Warren blast Biden for his stance on abortion funding

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.